September 2020
In this issue
Examine our bioanalytical assay list, new scientific publications, webinars, podcasts, and more, covering our full-service preclinical, clinical and manufacturing solutions…
Key Considerations for a Successful Ligand Binding Program
Preclinical to clinical bioanalytical expertise at Altasciences
Challenges in Early Phase Clinical Pharmacology Studies
Importance of integration and eliminating organizational silos
The Altascientist
Central nervous system (CNS) active drugs — complex considerations.
CONTINUE READING
- Webinars
Register for upcoming complimentary webinars and view the latest ones on-demand! - Podcasts
Listen to podcasts covering industry hot topics! - Up Close and Personal with…
Meet Joseph A. Francisco - Blog
Enjoy Dr. Francisco’s commentary on the FDA guidance related to COVID-19 vaccines, and other insightful posts.
Identifying Appropriate Outcome Measures and Methodology to Evaluate the Abuse, Misuse, Dependence, and Impairing Effects of CNS-Active Drugs in Healthy Volunteer and Patient Trials
Intraperitoneal Alfaxalone and Alfaxalone–Dexmedetomidine Anesthesia in Sprague–Dawley Rats (Rattus norvegicus)
Webinar — Choosing the Right CDMO for your Highly Potent Product Development
|
|
Altasciences CDMO facility is equipped with a 2,000-square-foot GMP high-potency/Grade C manufacturing and handling area paired with state-of-the-art fully qualified equipment and is managed by our highly trained team of experts. Watch this on-demand webinar to know more about our potent handling capabilities. |
|
|